Shmuel Cabilly

Shmuel Cabilly Overview

Shmuel Cabilly is a highly regarded scientist, an Angel Investor and an experienced Board Member of Several Companies. He currently holds three board and advisor roles including Board Member at Irody, Board Observer at Medasense, and Board Member at Pango. Dr. Cabilly previously worked for several companies including as the Co-Founder and a Chief Scientist of Ethrog Biotechnology, where he invented two dry-buffer technologies. The company was later sold to Invitrogen. Dr. Cabilly graduated from the Hebrew University (Ph.D., Immunology), and was a Post-Doctoral fellow at the City of Hope Research Institute heading a joint City of Hope/Genentech project where he developed a new technology for recombinant antibody production. This invention was patented in world patents, issued in the US 1989 and 2001. Today there are 20 drugs in the market based on this technology, including Herceptin, Rituxan, Traceba, Raptiva and Xolair.

Latest News

Sep 10, 2021 · www.globes.co.il

growth-positive

תכירו: ממציא הפטנט שיצר שוק של 44 מיליארד ד'

Dr. Shmuel Cabilly, the scientist who invented one of the most profitable patents in medicine in recent years, is investing in young biomed companies. His portfolio includes Radahil, Capital Point, Biokine from the KTB group (whose technology was recently sold to Bioline), Oranim (which recently received an investment from Orbimed and GE), NeuroDerm, Tritu, and others. Cabilly was the keynote speaker at a business-social event, Bio-Beer, organized by Orbimed in partnership with the law firm Greenberg Traurig. The event was attended by senior executives from the biomed industry.

InvestmentPartners

Team Members

1

Web & Social Links

Photos & Videos

No files yet

Shmuel Cabilly Internal

Recent Updates

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info